A recent study from Chandra Bhattacharya's (Chemistry and Biochemistry) laboratory developed a lipid nanoparticle platform that can deliver mRNA intravenously to the pancreas with an unprecedented 99% selectivity. This work was published in Advanced Materials, titled "Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas."

The findings highlight its potential for translational applications in protein replacement and CRISPR/Cas9-mediated gene editing for currently incurable pancreatic diseases, including pancreatic cancer and diabetes.